Compare FAX & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FAX | OVID |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 532.5M | 479.4M |
| IPO Year | N/A | 2017 |
| Metric | FAX | OVID |
|---|---|---|
| Price | $12.23 | $2.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $6.15 |
| AVG Volume (30 Days) | 213.8K | ★ 2.3M |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | ★ 12.09% | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $12.43 | $1.26 |
| 52 Week High | $16.37 | $3.11 |
| Indicator | FAX | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 30.28 | 41.03 |
| Support Level | N/A | $2.12 |
| Resistance Level | $14.69 | $2.67 |
| Average True Range (ATR) | 0.17 | 0.24 |
| MACD | -0.03 | -0.05 |
| Stochastic Oscillator | 10.48 | 4.30 |
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.